The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Official Title: A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Study ID: NCT04913337
Brief Summary: Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University of Southern California, Los Angeles, California, United States
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
UCLA Medical Center, Santa Monica, California, United States
Georgetown University Medical Center, Washington, District of Columbia, United States
Florida Cancer Specialists - Sarasota - SCRI, Sarasota, Florida, United States
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
START Midwest, LLC, Grand Rapids, Michigan, United States
Nebraska Cancer Specialists, Omaha, Nebraska, United States
Prisma Health - Upstate, Greenville, South Carolina, United States
University of Texas Southwestern Medical Center, Dallas, Texas, United States
MD Anderson Cancer Center, Houston, Texas, United States
NEXT Oncology, San Antonio, Texas, United States
Seoul National University Hospital, Seoul, , Korea, Republic of
Samsung Medical Center, Seoul, , Korea, Republic of
China Medical University Hospital, Taichung, , Taiwan
National Taiwan University Hospital, Taipei, , Taiwan